AtriCure Reports Third-Quarter Revenue of $154.5 Million, Updates 2026 Guidance
Revenue rose 15% year over year to $154.5 million. Net income was $4.1 million versus a $0.3 million loss a year earlier; adjusted EBITDA increased 51% to $26.8 million, and gross margin expanded to 77.3%. AtriCure projected full-year 2026 revenue of approximately $606 million to $610 million.
AtriCure, Inc. reported third-quarter 2026 revenue of $154.5 million, representing a 15% increase year-over-year. The company achieved a net income of $4.1 million, compared to a net loss of $0.3 million in the same period last year. Adjusted EBITDA rose 51% to $26.8 million, while gross margin expanded to 77.3%.
AtriCure also provided updated full-year 2026 revenue guidance, projecting a range of approximately $606 million to $610 million. Business growth was driven by the cryoSPHERE MAX probe, the EnCompass clamp, and AtriClip devices, despite a decline in minimally invasive ablation sales.